Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE:MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country.

  • Countries are negotiating prices with Merck and Pfizer Inc (NYSE:PFE). The U.S. government is paying $700 for each course of molnupiravir.
  • "The authorization of molnupiravir for compassionate use offers further therapy in the fight against COVID-19," Boitumelo Semete-Makokotlela, chief executive of SAHPRA, said.
  • But health department Deputy Director-General Nicholas Crisp told Reuters that an evaluation score from the National Essential Medicines List Committee indicated that Merck's pill would not be cost-effective.
  • "We are not planning to procure molnupiravir," Crisp said, adding that the advisory committee was yet to evaluate Pfizer's Paxlovid. 
  • However, the private sector can buy whatever is allowed by SAHPRA since medicines are not like vaccines sold to governments only, he added.
  • SAHPRA said that Pfizer had applied for authorization of use of Paxlovid, and it was considering the application.
  • Price Action: MRK shares are down 0.41% at $76.90 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.